Y-mAbs Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
BofA Merrill Lynch and Cowen acted as joint book-running managers for the offering.
The shares were offered by Y-mAbs pursuant to a registration statement that was declared effective by the
The offering was made only by means of a prospectus, copies of which may be obtained by contacting BofA Merrill Lynch, NC1-004-03-43,
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
Y-mAbs is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including two pivotal-stage product candidates—naxitamab and omburtamab—which target tumors that express GD2 and B7-H3, respectively.
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected trading commencement and closing dates. Words such as “expect” or “will” or similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, and the risk factors and other matters discussed in the Company’s filings with the
|Y-mAbs Therapeutics, Inc.
230 Park Avenue, suite 3350
New York, NY 10169
+1 646 885 8505
|Y-mAbs Therapeutics A/S
Agern Allé 11
+45 70 26 14 14
Source: Y-mAbs Therapeutics, Inc